Arecor Therapeutics plc
AREC.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £5 | £5 | £2 | £1 |
| % Growth | 10.5% | 90.3% | 107.5% | – |
| Cost of Goods Sold | £4 | £3 | £0 | £0 |
| Gross Profit | £2 | £5 | £2 | £1 |
| % Margin | 30.5% | 100% | 100% | 100% |
| R&D Expenses | £3 | £6 | £9 | £5 |
| G&A Expenses | £6 | £9 | £6 | £2 |
| SG&A Expenses | £6 | £9 | £6 | £2 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £3 | -£1 | -£1 | -£1 |
| Operating Expenses | £12 | £14 | £13 | £7 |
| Operating Income | -£11 | -£9 | -£12 | -£6 |
| % Margin | -211.7% | -200.6% | -485.2% | -516.1% |
| Other Income/Exp. Net | £0 | £0 | £0 | -£1 |
| Pre-Tax Income | -£11 | -£9 | -£11 | -£7 |
| Tax Expense | -£0 | -£0 | -£1 | -£1 |
| Net Income | -£10 | -£9 | -£9 | -£6 |
| % Margin | -202.6% | -187.1% | -385.4% | -532.7% |
| EPS | -0.31 | -0.28 | -0.32 | -0.27 |
| % Growth | -10.7% | 12.5% | -18.5% | – |
| EPS Diluted | -0.31 | -0.28 | -0.32 | -0.27 |
| Weighted Avg Shares Out | 33 | 31 | 29 | 23 |
| Weighted Avg Shares Out Dil | 33 | 31 | 29 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £1 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£10 | -£8 | -£10 | -£6 |
| % Margin | -200.9% | -183.5% | -418.7% | -541.2% |